Quimioprofilaxia da malária com mefloquina na amaz?nia brasileira

摘要

In a randomised double blind study 122 volunteers living in an endemic malarious area in Amazonian Rondonia State were divided into 4 groups to study malaria supression. The first group received 500mg of mefloquine every month, group II 250mg every two weeks, group III a tablet of Fansidar (500mg sulphadoxine + 25mg pyrimethamine) a week and group IVplacebo. Acute attacks of malaria occured in one individual in group I, 2 subject in group II, and 6 individuals in groups 111 e IV. Protection with mefloquine was significant compared with the placebo group. Both treatment regimens with mefloquine were effective supressants in an area of high prevalence of drug multiresistant Plasmodium falciparum transmission.